Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...
Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
ITM-11 significantly improved PFS and OS compared to everolimus in GEP-NET patients, meeting primary and secondary endpoints. Subgroup analyses showed ITM-11's efficacy across tumor grades and prior ...
NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
Pfizer Inc. experiences a mixed bag in the options market as its shares dip slightly. Currently, the stock is trading down 16 ...
--Longest losing streak since Feb. 25, 2020, when it fell for nine straight trading days --Worst nine-day stretch since the nine days ending April 11, 2025, when it fell 13.54% --Down 8.25% ...
Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find ...
Pfizer's Tukysa improved progression-free survival in first-line HER2+ metastatic breast cancer, showing strong efficacy and ...
Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...
J&J reports today, just two weeks after Pfizer secured certainty on tariffs and drug pricing. Analysts expect to hear about ...
Pfizer (PFE) stock is in focus as a Phase 3 trial for its Tukysa cancer drug as a first-line maintenance option in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback